US2007020675A1PendingUtilityA1

Modulation of endothelial lipase expression

Assignee: DOBIE KENNETH WPriority: May 31, 2002Filed: Aug 9, 2006Published: Jan 25, 2007
Est. expiryMay 31, 2022(expired)· nominal 20-yr term from priority
Inventors:Kenneth Dobie
C12Y 301/01003C07H 21/00C12N 2310/321C12N 2310/315C12N 2310/11C12N 2310/341C12N 15/1137C07H 21/04C12N 2310/346C12N 2310/3341
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.

Claims

exact text as granted — not AI-modified
1 . A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding endothelial lipase, wherein said compound specifically hybridizes with said nucleic acid molecule encoding endothelial lipase (SEQ ID NO: 4) and inhibits the expression of endothelial lipase.  
     
     
         2 . The compound of  claim 1  comprising 12 to 50 nucleobases in length.  
     
     
         3 . The compound of  claim 2  comprising 15 to 30 nucleobases in length.  
     
     
         4 . The compound of  claim 1  comprising an oligonucleotide.  
     
     
         5 . The compound of  claim 4  comprising an antisense oligonucleotide.  
     
     
         6 . The compound of  claim 4  comprising a DNA oligonucleotide.  
     
     
         7 . The compound of  claim 4  comprising an RNA oligonucleotide.  
     
     
         8 . The compound of  claim 4  comprising a chimeric oligonucleotide.  
     
     
         9 . The compound of  claim 4  wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.  
     
     
         10 . The compound of  claim 1  having at least 70% complementarity with a nucleic acid molecule encoding endothelial lipase (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of endothelial lipase.  
     
     
         11 . The compound of  claim 1  having at least 80% complementarity with a nucleic acid molecule encoding endothelial lipase (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of endothelial lipase.  
     
     
         12 . The compound of  claim 1  having at least 90% complementarity with a nucleic acid molecule encoding endothelial lipase (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of endothelial lipase.  
     
     
         13 . The compound of  claim 1  having at least 95% complementarity with a nucleic acid molecule encoding endothelial lipase (SEQ ID NO: 4) said compound specifically hybridizing to and inhibiting the expression of endothelial lipase.  
     
     
         14 . The compound of  claim 1  having at least one modified internucleoside linkage, sugar moiety, or nucleobase.  
     
     
         15 . The compound of  claim 1  having at least one 2′-O-methoxyethyl sugar moiety.  
     
     
         16 . The compound of  claim 1  having at least one phosphorothioate intemucleoside linkage.  
     
     
         17 . The compound of  claim 1  having at least one 5-methylcytosine.

Join the waitlist — get patent alerts

Track US2007020675A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.